BioPharmSignal logoBioPharmSignal

Biotech News

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026

Aligos Therapeutics (ALGS)Aligos TherapeuticsCompany update

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from five

Related news

ALGSAligos Therapeutics2026-10-05 20:05 EST

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

MLYSMineralys Therapeutics2026-06-14 14:00 EST

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

MLYSMineralys Therapeutics2026-10-09 13:00 EST

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

VKTXViking Therapeutics2026-09-22 11:05 EST

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

BLTEBelite Bio2026-07-20 12:00 EST

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

VKTXViking Therapeutics2026-11-03 21:30 EST

Viking Therapeutics to Participate at Upcoming Investor Conferences

SGMTSagimet Biosciences2026-10-09 11:00 EST

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

CVRXCVRx2026-09-29 20:30 EST

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

View all latest news

Aligos Therapeutics

Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B...

Recent company news

ALGSAligos Therapeutics2026-11-06 13:00 EST

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

ALGSAligos Therapeutics2026-11-05 21:05 EST

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026

ALGSAligos Therapeutics2026-10-05 20:05 EST

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Stock data

Close
4.51 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States